Bruce Steel

Bruce D. Steel has served as BioMed Ventures Managing Director since September 2010. From 2005 until its acquisition in 2008, Bruce was Chief Executive Officer and Co-Founder of Rincon Pharmaceuticals, a genetic engineering biotechnology and biofuels company. Bruce was also previously Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. He received his Bachelor of Arts Degree from Dartmouth College and his Masters of Business Administration Degree from the Marshall School of Business at the University of Southern California. Mr. Steel holds the designation of Chartered Financial Analyst.

Important Safety Information:

The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.